#### §212.50

## Subpart F—Production and Process Controls

### §212.50 What production and process controls must I have?

You must have adequate production and process controls to ensure the consistent production of a PET drug that meets the applicable standards of identity, strength, quality, and purity.

- (a) Written control procedures. You must have written production and process control procedures to ensure and document that all key process parameters are controlled and that any deviations from the procedures are justified.
- (b) Master production and control records. You must have master production and control records that document all steps in the PET drug production process. The master production and control records must include the following information:
- (1) The name and strength of the PET drug:
- (2) If applicable, the name and radioactivity or other measurement of each active pharmaceutical ingredient and each inactive ingredient per batch or per unit of radioactivity or other measurement of the drug product, and a statement of the total radioactivity or other measurement of any dosage unit:
- (3) A complete list of components designated by names and codes sufficiently specific to indicate any special quality characteristic:
- (4) Identification of all major pieces of equipment used in production;
- (5) An accurate statement of the weight or measurement of each component, using the same weight system (metric, avoirdupois, or apothecary) for each component. Reasonable variations are permitted in the amount of component necessary if they are specified in the master production and control records;
- (6) A statement of action limits on radiochemical yield, i.e., the minimum percentage of yield beyond which investigation and corrective action are required;
- (7) Complete production and control instructions, sampling and testing procedures, specifications, special notations, and precautions to be followed; and

- (8) A description of the PET drug product containers, closures, and packaging materials, including a specimen or copy of each label and all other labeling.
- (c) Batch production and control records. Each time a batch of a PET drug is produced, a unique batch production and control record must be created. The batch production record must include the following information:
- (1) Name and strength of the PET drug;
- (2) Identification number or other unique identifier of the specific batch that was produced:
- (3) The name and radioactivity or other measure of each active pharmaceutical ingredient and each inactive ingredient per batch or per unit of radioactivity or other measurement of the drug product;
- (4) Each major production step (obtained from the approved appropriate master production and control record);
- (5) Weights (or other measure of quantity) and identification codes of components:
- (6) Dates of production steps and times of critical production steps;
- (7) Identification of major pieces of equipment used in production of the batch;
  - (8) Testing results;
  - (9) Labeling:
- (10) Initials or signatures of persons performing or checking each significant step in the operation; and
- (11) Results of any investigations conducted.
- (d) Area and equipment checks. The production area and all equipment in the production area must be checked to ensure cleanliness and suitability immediately before use. A record of these checks must be kept.
- (e) In-process materials controls. Process controls must include control of inprocess materials to ensure that the materials are controlled until required tests or other verification activities have been completed or necessary approvals are received and documented.

- (f) Process verification. (1) For a PET drug for which each entire batch undergoes full finished-product testing to ensure that the product meets all specifications, process verification, as described in paragraph (f)(2) of this section, is not required.
- (2) When the results of the production of an entire batch of a PET drug are not fully verified through finishedproduct testing or when only the initial sub-batch in a series is tested, the PET drug producer must demonstrate that the process for producing the PET drug is reproducible and is capable of producing a drug product that meets the predetermined acceptance criteria. Process verification activities and results must be documented. Documentation must include the date and signature of the individual(s) performing the verification, the monitoring and control methods and data, and the major equipment qualified.

#### Subpart G—Laboratory Controls

#### § 212.60 What requirements apply to the laboratories where I test components, in-process materials, and finished PET drug products?

- (a) Testing procedures. Each laboratory used to conduct testing of components, in-process materials, and finished PET drug products must have and follow written procedures for the conduct of each test and for the documentation of the results.
- (b) Specifications and standards. Each laboratory must have sampling and testing procedures designed to ensure that components, in-process materials, and PET drug products conform to appropriate standards, including established standards of identity, strength, quality, and purity.
- (c) Analytical methods. Laboratory analytical methods must be suitable for their intended use and must be sufficiently sensitive, specific, accurate, and reproducible.
- (d) Materials. The identity, purity, and quality of reagents, solutions, and supplies used in testing procedures must be adequately controlled. All solutions that you prepare must be properly labeled to show their identity and expiration date.

- (e) *Equipment*. All equipment used to perform the testing must be suitable for its intended purposes and capable of producing valid results.
- (f) Equipment maintenance. Each laboratory must have and follow written procedures to ensure that equipment is routinely calibrated, inspected, checked, and maintained, and that these activities are documented.
- (g) Test records. Each laboratory performing tests related to the production of a PET drug must keep complete records of all tests performed to ensure compliance with established specifications and standards, including examinations and assays, as follows:
- (1) A suitable identification of the sample received for testing.
- (2) A description of each method used in the testing of the sample, a record of all calculations performed in connection with each test, and a statement of the weight or measurement of the sample used for each test.
- (3) A complete record of all data obtained in the course of each test, including the date and time the test was conducted, and all graphs, charts, and spectra from laboratory instrumentation, properly identified to show the specific component, in-process material, or drug product for each lot tested.
- (4) A statement of the results of tests and how the results compare with established acceptance criteria.
- (5) The initials or signature of the person performing the test and the date on which the test was performed.

# § 212.61 What must I do to ensure the stability of my PET drug products through expiry?

- (a) Stability testing program. You must establish, follow, and maintain a written testing program to assess the stability characteristics of your PET drug products. The test methods must be reliable, meaningful, and specific. The samples tested for stability must be representative of the lot or batch from which they were obtained and must be stored under suitable conditions.
- (b) Storage conditions and expiration dates. The results of such stability testing must be documented and used in determining appropriate storage conditions and expiration dates and times